With maturity comes confidence: EBCTCG tamoxifen update

被引：17

作者：

Chia, Stephen K. ^{[1
]}

Wolff, Antonio C. ^{[2
]}

机构：

[1] Univ British Columbia, British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[2] Johns Hopkins Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

LANCET | 2011年 / 378卷 / 9793期

关键词：

ADJUVANT ENDOCRINE THERAPY; BREAST-CANCER; WOMEN;

D O I：

10.1016/S0140-6736(11)61128-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：747 / 749

页数：3

共 17 条

[1] Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Ravdin, Peter M. ;

Farrar, William B. ;

Burton, Gary V. ;

Ketchel, Steven J. ;

Cobau, Charles D. ;

Levine, Ellis G. ;

Ingle, James N. ;

Pritchard, Kathleen I. ;

Lichter, Allen S. ;

Schneider, Daniel J. ;

Abeloff, Martin D. ;

Henderson, I. Craig ;

Muss, Hyman B. ;

Green, Stephanie J. ;

Lew, Danika ;

Livingston, Robert B. ;

Martino, Silvana ;

Osborne, C. Kent .

LANCET, 2009, 374 (9707) :2055-2063

[2]

Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI [10.1200/JCO.2009.26.3756, 10.1200/JOP.000082]

[3] Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial [J].

Cuzick, Jack ;

Sestak, Ivana ;

Baum, Michael ;

Buzdar, Aman ;

Howell, Anthony ;

Dowsett, Mitch ;

Forbes, John F. .

LANCET ONCOLOGY, 2010, 11 (12) :1135-1141

[4] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J].

Davies, C. ;

Godwin, J. ;

Gray, R. ;

Clarke, M. ;

Darby, S. ;

McGale, P. ;

Wang, Y. C. ;

Peto, R. ;

Pan, H. C. ;

Cutter, D. ;

Taylor, C. ;

Ingle, J. .

LANCET, 2011, 378 (9793) :771-784

[5] Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer [J].

Dignam, James J. ;

Dukic, Vanja ;

Anderson, Stewart J. ;

Mamounas, Eleftherios P. ;

Wickerham, D. Lawrence ;

Wolmark, Norman .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 116 (03) :595-602

[6] Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen [J].

Dowsett, Mitch ;

Cuzick, Jack ;

Ingle, Jim ;

Coates, Alan ;

Forbes, John ;

Bliss, Judith ;

Buyse, Marc ;

Baum, Michael ;

Buzdar, Aman ;

Colleoni, Marco ;

Coombes, Charles ;

Snowdon, Claire ;

Gnant, Michael ;

Jakesz, Raimund ;

Kaufmann, Manfred ;

Boccardo, Francesco ;

Godwin, Jon ;

Davies, Christina ;

Peto, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :509-518

[7]

Ferlan J, GLOBOCAN 2008 CANC F

[8] Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer [J].

Hackshaw, Allan ;

Roughton, Michael ;

Forsyth, Sharon ;

Monson, Kathryn ;

Reczko, Krystyna ;

Sainsbury, Richard ;

Baum, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (13) :1657-1663

[9]

Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.5858/134.6.907, 10.1200/JCO.2009.25.6529, 10.1200/JOP.777003]

[10] Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J].

Harvey, JM ;

Clark, GM ;

Osborne, CK ;

Allred, DC .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1474-1481

← 1 2 →